FluoroPharma Medical, Inc.: 10-Q filed 2015-11-16

Name: FluoroPharma Medical, Inc.: 10-Q filed 2015-11-16
Creator: FluoroPharma Medical, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What FluoroPharma Medical, Inc. reported in its quarterly report filed 2015-11-16 (fiscal Q3 2015): 23 published measures, 64 facts as tagged in accession 0001415889-15-003747.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-16
Fiscal period: fiscal Q3 2015
Accession: 0001415889-15-003747 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All FluoroPharma Medical, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	2,046,593	USD
At 2014-12-31	820,191	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	-6,911,005	USD
At 2014-12-31	-4,796,635	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	1,301,122	USD
At 2014-12-31	252,145	USD
At 2014-09-30	59,769	USD
At 2013-12-31	1,143,175	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	104,908	USD	92
2015-01-01 to 2015-09-30	-1,897,228	USD	273
2014-07-01 to 2014-09-30	-1,016,825	USD	92
2014-01-01 to 2014-09-30	-4,240,693	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	-1,709,450	USD	273
2014-01-01 to 2014-09-30	-2,861,969	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	6,564	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	2,722,457	USD	273
2014-01-01 to 2014-09-30	1,566,275	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	35,970	USD	273
2014-01-01 to 2014-09-30	212,288	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-31,194,268	USD
At 2014-12-31	-28,866,683	USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	0	USD/shares	92
2015-01-01 to 2015-09-30	-0.08	USD/shares	273
2014-07-01 to 2014-09-30	-0.04	USD/shares	92
2014-01-01 to 2014-09-30	-0.16	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	5,712	USD
At 2014-12-31	11,727	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	1,712,586	USD
At 2014-12-31	450,924	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	240,851	USD	92
2015-01-01 to 2015-09-30	398,775	USD	273
2014-07-01 to 2014-09-30	39,467	USD	92
2014-01-01 to 2014-09-30	40,075	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	8,957,598	USD
At 2014-12-31	5,616,826	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	1,672,185	USD
At 2014-12-31	1,064,480	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2015-09-30	328,295	USD
At 2014-12-31	357,540	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	784,592	USD	92
2015-01-01 to 2015-09-30	2,350,820	USD	273
2014-07-01 to 2014-09-30	1,466,319	USD	92
2014-01-01 to 2014-09-30	3,900,048	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	291,618	USD	92
2015-01-01 to 2015-09-30	576,824	USD	273
2014-07-01 to 2014-09-30	641,445	USD	92
2014-01-01 to 2014-09-30	1,232,939	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	30,366,011	shares
At 2014-12-31	29,197,497	shares

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-37,932	USD	92
2015-01-01 to 2015-09-30	-2,327,585	USD	273
2003-12-13 to 2015-09-30	-31,194,268	USD	4310
2014-07-01 to 2014-09-30	-1,151,878	USD	92
2014-01-01 to 2014-09-30	-4,655,699	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	492,974	USD	92
2015-01-01 to 2015-09-30	1,773,996	USD	273
2014-07-01 to 2014-09-30	824,874	USD	92
2014-01-01 to 2014-09-30	2,667,109	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	889,500	USD	92
2015-01-01 to 2015-09-30	453,592	USD	273
2014-07-01 to 2014-09-30	449,494	USD	92
2014-01-01 to 2014-09-30	-340,645	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	607,705	USD	273
2014-01-01 to 2014-09-30	357,060	USD	273

Inspect the source

Entity: FluoroPharma Medical, Inc. / CIK 0001402785
Captured: 2026-09-23 02:52 UTC
SEC response SHA-256: 4d77d986a03178d60883d667e91c227ed829415c26872c73ee7ae0df9851ff14

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001402785.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))